Kornimate/medical-research-clean huggingface dataset:
cerebral embolism (ce) in catheter ablation of atrial fibrillation (af)

Conditions: Atrial Fibrillation

Summary: radiofrequency catheter ablation of atrial fibrillation (af) induces a procoagulant state, which leads to an acute risk for symptomatic cerebral embolism (ce) of approximately 1%. the induction of a procoagulant state has been studied in pulmonary vein isolation (pvi) with a non-cooled tip catheter. the induction of a procoagulant state using a cooled-tip catheter has not been studied yet. due to the avoidance of high endocardial temperatures, it can be expected that these procedures induce a lower level of procoagulation. recent studies showed an 11% incidence of ce on diffusion weighted (dw) mri in patients undergoing cooled-tip catheter ablation of af. in this study there will be used to different catheters, the cooled-tip catheter and the pvac gold catheter. since the pvac gold catheter is equipped with non-cooled electrodes, the risk of endothelial scarring, local thrombosis and ce may be increased. the goal of this study is to determine the effect of two different ablation catheters on the induction of a procoagulant state and the incidence of ce on dw-mri in patients with af undergoing pvi. our hypothesis is that patients with af undergoing pvi using the pvac gold catheter will show a higher rise in procoagulation and a higher incidence of ce on dw-mri than patients with af undergoing pvi with the cooled-tip catheter.

a total of 70 patients scheduled for a first ablation of paroxysmal af will be included. patients will be 1:1 randomized to pvi using the pvac gold catheter or the cooled-tip catheter. a control group of 20 patients with af but without undergoing ablation is included for neuropsychological testing. before the procedure, the procoagulant state will be assessed by measuring several markers of endothelial damage, activated coagulation, fibrinolysis and by measurement of fibrinogen and thrombin generation. measurements will be repeated during and after the procedure. documentation of the formation of ce will be established by performing a dw-mri before and after the ablation. the proportion of symptomatic ce will be quantified by neuropsychological tests and questionnaires. finally, transcranial doppler will be performed during the entire procedure to quantify the number and pattern of cerebral microembolic signals (mes).

Eligibility criteria:
inclusion criteria: * suffering from drug-refractory paroxysmal atrial fibrillation * scheduled for first ablation procedure exclusion criteria: * contra-indications for dw-mri * previous af-ablation * minors * any patient unable to undergo neuropsychological testing due to mental retardation

Keywords: atrial fibrillation cerebral embolism catheter ablation
mechanical thrombectomy for acute lower limb deep vein thrombosis in tumor patients

Conditions: Cancer Patients With Acute Lower Limb Deep Vein Thrombosis (DVT)

Summary: this study will conduct a prospective single blind controlled study on the clinical efficacy and safety indicators of 50 cancer patients with acute lower limb deep vein thrombosis (dvt). the patients were randomly divided into an experimental group (improved mechanical thrombectomy (pmt) group) and a control group (traditional simple anticoagulation group) using the "envelope method", with 25 cases each. after the end of treatment, clinical prognosis evaluations were conducted on the patient's vital signs, symptoms and signs, lower limb doppler ultrasound examination, patient pts score (villalta score), quality of life score (qol), etc. at 3, 6, and 12 months. adverse events, the presence or absence of thrombus recurrence, and re surgical intervention were recorded. this study is expected to propose a new strategy for the treatment of acute dvt in cancer patients, thereby improving the overall level of vte prevention and treatment.


Eligibility criteria:
inclusion criteria: * 1) between the ages of 18 and 75; 2) suffering from acute lower limb deep vein thrombosis (dvt) with a duration of less than 14 days from onset; 3) thrombosis involving the iliac vein, femoral vein, or popliteal vein; 4) the patient has been diagnosed with tumors, including benign or malignant tumors, including surgical or conservative treatment; 5) sign an informed consent form. exclusion criteria: * 1) patients with a history of deep vein thrombosis of the same lower limb in the past; 2) patients with plasma cr levels greater than 180umol/l; 3) patients with contraindications to thrombolytic drugs; 4) patients with concomitant inferior vena cava thrombosis or simple calf intermuscular vein thrombosis; 5) patients who are known to be allergic to heparin, low molecular weight heparin, contrast agents, etc; 6) patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months; 7) pregnant and lactating women; 8) patients with a life expectancy of less than 6 months, or those with other diseases that may cause difficulty in testing or significantly shorten the patient's life expectancy (\<1 year), including severe liver disease, cardiac insufficiency, etc; 9) patients with autoimmune thrombotic disease; 10) patients who are unable or unwilling to participate in this trial.
vibration intervention to improve bone and muscle in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy is a group of disorders characterized by lack of coordination in the muscles, loss of movement, and speech disturbances. these disorders are caused by injuries to the brain that occur during fetal development or near the time of birth. the purpose of this study is to determine the effects of high frequency, low magnitude vibration on bone and muscle in children with cerebral palsy.

the extent of bone mass built up during childhood and adolescence is the most important determinant of osteoporosis later in life. some disabled children, such as those with cerebral palsy, are particularly vulnerable to low bone mass accumulation due to decreased mobility and weight-bearing. these children also have poor muscle strength and control, which limits function and contributes to the lack of mechanical stimulation needed to build bone mass. the most common treatment for these children is physical therapy, which is time- and labor-intensive and may not be adequately available to them. whole body vibration has shown promise as an alternative method for stimulating increases in bone mass and improvements in muscle. the purpose of this study is to evaluate the effects of high frequency, low magnitude vibration on bone and muscle in children with cerebral palsy. this intervention may be useful as a noninvasive, nonpharmacological treatment for low bone mass and poor muscle function in these children. this study will last 1 year. all participants will visit the hospital 3 times, at study entry and months 6 and 12. at each visit, height and weight will be measured, muscle strength and balance will be tested, and bones and muscles in the spine and lower leg will be imaged with computed tomography (ct), a special x-ray machine. participants will be randomly assigned to one of two groups. for this study, all participants will be asked to stand for 10 minutes every day for 1 year. for group 1, a vibrating platform will be used for the 10-minute standing sessions during the first half of the study but not during the second half of the study. for group 2, this will be reversed and the vibrating platform will not be used during the first half of the study but will be used during the second half of the study.

Eligibility criteria:
inclusion criteria: * diagnosis of cerebral palsy * low vertebral bone density * able to stand for 10 minutes with handheld support * parent or guardian willing to provide informed consent exclusion criteria: * surgery, casting, or receipt of botulinum toxin in the 12 months prior to study entry * planned surgery, casting, or receipt of botulinum toxin in the 12 months after study entry * metal rods or plates in tibia or lumbar spine * severe scoliosis (greater than 20 degrees) or bowing of tibia * medical condition other than cerebral palsy affecting bone or muscle * require corticosteroids or seizure medication (phenytoin)

Keywords: vibration bone density
clinical evaluation of some local antimicrobial agents' adjunctive effects on periodontal parameters and halitosis

Conditions: Halitosis

Summary: the aim of this trial was to establish the clinical efficacy of listerine and chlorhexidine (chx) when used as a cooling agent with ultrasonic instrumentation, on periodontal parameters and halitosis. ninety patients with periodontal disease participated for the study. individuals were randomly selected to a control and test groups. at baseline, all subjects completed a questionnaire and carried out an examination. standard periodontal outcome variables were assessed. for both groups, the plaque index (pi), gingival index (gi), pocket depth (pd), bleeding on probing (bop) and clinical attachment level (cal) scores were enrolled at baseline and after 30 days. volatile sulphur compound (vsc) levels were evaluated by a halimeter (interscan corp., chatsworth, ca, usa) at baseline (t0), immediately after treatment (t1), and at 7 (t2), 14 (t3) and 30 days (t4).


Eligibility criteria:
inclusion criteria: * in the present trial, who had periodontitis from patients undergoing periodontal treatment at the department of periodontology of our institution exclusion criteria: * individuals who presented any systemic disorders which cause halitosis (diabetes mellitus, nephropathy, liver disease, gastrointestinal diseases, respiratory problems), pregnancy or lactation, individuals who had taken antibiotics over the last 6 months or permanently used any drugs, individuals who had any form of periodontal treatment within 6 months prior to the study.

Keywords: listerine, chx
best management of sigmoid volvulus: a prospective randomized trial

Conditions: Intestinal Volvulus; Colon, Sigmoid

Summary: the purpose of this study is to obtain a better understanding of the best management of left-sided colonic emergencies.

participants: patients 18 years or older presenting to kamuzu central hospital in lilongwe malawi with sigmoid volvulus will be eligible for inclusion. procedures (methods): this is a prospective randomized trial. subjects will be randomized during surgery to receive resection and anastomosis or mesosigmoidopexy (for non-gangrenous sigmoid volvulus), and resection and anastomosis or hartmann's procedure (for gangrenous sigmoid volvulus).

Eligibility criteria:
inclusion criteria: * clinical suspicion of sigmoid volvulus as deemed by the surgeon on duty exclusion criteria: * pregnancy, * age under 18 years, * prisoners

Keywords: intestinal volvulus colon, sigmoid anastomosis, surgical anastomotic leak malawi developing country
randomized study of folic acid therapy for hyperhomocysteinemia in patients with end stage renal disease receiving hemodialysis

Conditions: End Stage Renal Disease; Hyperhomocysteinemia

Summary: objectives: i. compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia. ii. determine the requirement of co-supplementation with extra pyridoxine (vitamin b6) and cyanocobalamin (vitamin b12) daily in these patients. iii. assess the safety and tolerability of this therapy in these patients.

protocol outline: this is a randomized, placebo controlled study. patients are stratified according to prestudy homocysteine levels (above or below average). patients are randomized to receive placebo or one of two doses of oral folic acid, with or without pyridoxine and cyanocobalamin. arm i: patients receive oral placebo daily. arm ii: patients receive oral pyridoxine, cyanocobalamin, and oral placebo daily. arm iii: patients receive oral pyridoxine, cyanocobalamin, and folic acid daily. arm iv: patients receive oral pyridoxine and cyanocobalamin plus a higher dose of folic acid daily. arm v: patients receive oral placebo and oral folic acid daily. arm vi: patients receive oral placebo and higher dose folic acid daily. treatment continues for 8 weeks. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * diagnosis of end stage renal disease requiring regular hemodialysis treatment 3 times weekly * baseline predialysis total homocysteine concentration in plasma greater than 16 micromoles/l * no prior or concurrent pernicious anemia * no blood smear examination showing unexplained macrocytosis --prior/concurrent therapy-- * chemotherapy: no concurrent chemotherapy for cancer * other: no concurrent levodopa or carbidopa no concurrent penicillamine or trimethoprim-sulfonamide combination no concurrent antiviral therapy no concurrent anticonvulsants --patient characteristics-- * hematopoietic: hematocrit at least 25% * other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no parkinson's disease no convulsions or epilepsy requiring treatment no lactose intolerance or allergy to milk products no history of allergic sensitization following administration of folic acid, pyridoxine (vitamin b6), or cyanocobalamin (vitamin b12) no vitamin b12 concentration below lower limit of normal (150 picamole/l) no untreated hypothyroidism or psoriasis

Keywords: cardiovascular and respiratory diseases end stage renal disease hyperhomocysteinemia rare disease renal and genitourinary disorders
effect of neuromuscular electrical stimulation of lower limbs on improving exercise self-efficacy, dyspnea during activity and fatigue in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease (COPD); Neuromuscular Electrical Stimulation (NMES); Exercise Self-Efficacy; Dyspnea During Activity; Fatigue

Summary: patients diagnosed with copd who meet the inclusion and exclusion criteria, either inpatients or outpatients, will be informed about the study'sstudy's purpose and procedures by the principal investigator. after understanding their rights, they will provide informed consent.

the process of the experiment the study adopts a quasi-experimental design with convenience sampling. data collection will be done through structured questionnaires. patients who meet the inclusion criteria will be referred by physicians, and before enrollment, a verbal introduction will be given explaining the study's purpose, the questionnaire, and the intervention procedure and duration. the experimental group will participate in both pulmonary rehabilitation exercises and an additional intervention of lower limb neuromuscular electrical stimulation, 30 minutes per session, three times per week, for eight weeks. the control group will only participate in pulmonary rehabilitation exercises. neuromuscular electrical stimulation should continue for 4 to 8 weeks. questionnaires will be administered before the intervention and at the 2nd, 4th, 6th, and 8th weeks post-intervention, including basic information, modified medical research council dyspnea scale, manchester copd fatigue scale, and self-efficacy for exercise scale. data collection will take approximately 25 minutes, and questionnaires will be personally retrieved by the researcher.

Eligibility criteria:
inclusion criteria: * patients diagnosed with copd as per pulmonary function reports, with post-bronchodilator fev1/fvc ratio \< 0.7, confirmed as mild to severe copd by physician, without acute exacerbation, aged 18 or above, enrolled in a pulmonary rehabilitation program, able to communicate clearly in mandarin or taiwanese, and without history of a psychiatric disorders. exclusion criteria: * patients unable to comply with long-term follow-up for lower limb neuromuscular electrical stimulation intervention, those with cardiac pacemakers, lower limb bone, joint, or neuromuscular diseases, obesity (bmi \>35 kg/m2), or systemic vascular diseases (e.g., lupus erythematosus).

Keywords: chronic obstructive pulmonary disease (copd) neuromuscular electrical stimulation (nmes) exercise self-efficacy dyspnea during activity fatigue
endorotor® ablation of barrett's esophagus: safety and feasibility study

Conditions: Barretts Esophagus With Dysplasia

Summary: the aim of this study is to assess the safety and feasibility of the endorotor® for the ablation of barrett's esophagus.

prospective pilot study, to be performed in 30 patients with barrett's esophagus that have an indication for ablation treatment. these include patients with low grade dysplasia (lgd), high grade dysplasia (hgd) or residual barrett's after a complete endoscopic resection of a lesion containing hgd or esophageal adenocarcinoma. ablation treatment will be performed by the endorotor ablation device, followed by surveillance endoscopy at 3 months where the feasibility for ablation will be assessed. during the 3 months follow-up, all adverse events such as perforation, post-procedural bleeding, stricture, and pain will be registered. the endorotor® system is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. the endorotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.

Eligibility criteria:
inclusion criteria: * written informed consent. * age equal to or above 18 years (adult). * minimum (residual) barrett's length of 2 cm and a maximum length of 5 cm (c0-5m2-5 according to the prague classification) * scheduled barrett's ablation for: * histologically proven intestinal metaplasia with either high- or low-grade dysplasia in the absence of any visible lesion, * residual barrett's mucosa after complete endoscopic resection (for visible lesions containing hgd or eac.) (emr \<50% of the circumference) * favorable anatomy (e.g. straight esophagus, no previous anti-reflux procedure) that allows performing endoscopic treatment with the endorotor®. exclusion criteria: * presence of a visible lesion suspicious of early esophageal cancer or has a high chance of harboring cancer, or biopsy proven cancer. * in case of previous emr: emr specimen showing deep submucosal invasion (\> 500μm), poorly to undifferentiated cancer (g3 or g4), lymphovascular invasion, or positive vertical margins. * in case of previous emr: \> 50% circumference. * any prior endoscopic ablation treatment or dilation for esophageal stenosis. * significant esophageal stenosis, preventing the passage of the therapeutic endoscope. * evidence of portal hypertension, esophageal varices, etc. * an interval \< 6 weeks between emr and endorotor treatment. * an interval of \> 6 months after the last high resolution endoscopy with biopsies containing low or high grade dysplasia. * unable to undergo endoscopic procedure using sedation analgesics. * anti-coagulant therapy (apart from monotherapy aspirin) that cannot be discontinued prior to the procedure, or uncorrectable hemostatic disorders.
oral versus parental progesterone in the management of preterm labor

Conditions: Preterm Labor

Summary: preterm birth, defined as delivery at less than 37 weeks gestation, complicates approximately 12% of pregnancies in the united states preterm delivery has been, and remains, the most important challenge to modern obstetrics. in 2009, 13 million babies were born preterm, 11 million in africa and asia and 500,000 in the usa, the highest rates of preterm birth are in africa (11.9%) and north america (10.6%)


Eligibility criteria:
inclusion criteria: 1. past history of one or more spontaneous preterm labor. 2. singleton pregnancy. 3. pregnancy of less than 20 weeks of gestation exclusion criteria: 1. women on tocolytic drugs . 2. underwent cervical cerclage in this pregnancy . 3. multiple gestations . 4. major fetal congenital malformations . 5. pregnancy 0f more than 20 weeks gestation .
adenosine vasodilator independent stenosis evaluation ii - advise ii

Conditions: Cardiovascular Disease

Summary: to assess the clinical value of ifr to characterize, without concomitant administration of hyperemic agents and outside a specified range of ifr values, coronary stenosis severity as determined with fractional flow reserve (ffr)


Eligibility criteria:
inclusion criteria: * - patient must be \> 18 and \< 85 years of age * willing to participate and able to understand, read and sign the informed consent document before the planned procedure * eligible for coronary angiography and/or percutaneous coronary intervention * coronary artery disease with at least 1 or more visually assessed coronary stenoses (\>40% diameter stenosis) in native major epicardial vessel or its branches by coronary angiogram. * stable angina or acute coronary syndromes (non-culprit vessels only and outside of primary intervention during acute myocardial infarction) exclusion criteria: * - known contraindication to adenosine administration * implanted temporary or permanent artificial pacemakers, left bundle branch block (lbbb), 1st and 2nd degree av block * stemi or non stemi within 48 hours of procedure * any contraindications for ffr interrogation or percutaneous coronary intervention (pci) as determined by the investigator * severe vessel tortuosity and/or severe calcification by angiogram * significant valvular pathology (moderate or severe as/ar/ms/mr) * previous coronary artery bypass surgery with patent grafts to the interrogated vessel * weight \>200kg (441 lbs.) * hemodynamic instability at the time of intervention (heart rate\<50 beats per minute, systolic blood pressure \<90mmhg) balloon pump * significant hepatic disease, renal disease, lung disease (pulmonary chronic pulmonary obstructive disease) and/or malignant disease with unfavorable prognosis or presenting with abnormal serum laboratory values that the physician believes is clinically significant * contraindication to antithrombotic regimen or anticoagulation therapy * history of or known reaction or sensitivity to contrast agent and is unable to be pre-medicated * left main stenosis, tandem stenosis separated by more than 5 mm that require separate pressure guide wire interrogation or pci (not to be interrogated or treated as a single stenosis), or total occlusions * known left ventricular ejection fraction (lvef) \<30%
timing of treatment completion in staged selective laser trabeculoplasty (slt): early vs. late completion

Conditions: Glaucoma

Summary: this study will evaluate the effect of the timing of treatment completion in two-staged selective laser trabeculoplasty therapy on intraocular pressure lowering effect.

slt therapy is used as an iop lowering agent in patients with glaucoma. it is unknown whether the timing of a 2-staged approach to the laser therapy will result in better iop lowering effect. this study will evaluate the timing (early vs. late completion of slt therapy) and determined the iop lowering effect following the interventions. arm 1: early completion slt 180 degrees of slt on day 1, 180 degrees of slt on the other 180 degrees on day 2 arm 2: late completion slt 180 degrees of slt on day 1, 180 degrees of slt on the other 180 degrees at the 1 month follow up visit. primary outcome: iop (mmhg).

Eligibility criteria:
inclusion criteria: * 18 years of age * primary open angle glaucoma or pseudoexfoliation glaucoma exclusion criteria: * unable to give informed consent

Keywords: glaucoma laser trabeculoplasty
sustained acoustic medicine ultrasound diathermy clinical performance

Conditions: Measurement of Diathermy on Anatomical Locations of the Body

Summary: the purpose of this study is to measure diathermy performance of sustained acoustic medicine devices with commercially available ultrasound gel coupling patches.


Eligibility criteria:
inclusion criteria: • healthy volunteer exclusion criteria: * is pregnant/nursing. * has an active infection, open sores, or wounds in the treatment area.